Savara
SVRA
4.68
-0.20
-4.10%
Savara
US · SVRA
#3247 by market cap
4.68
-0.20
-4.10%
Live - 5344 symbols - heartbeat 85s ago
· 2026-10-08 10:11
Pre-market
4.88
0.00%
After-hours
4.98
+1.95%
Overnight
4.88
0.00%
- Market cap
- 961.55M
- P/E (TTM)i
- -8.07
- P/Bi
- 6.70
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on SVRA?
Anonymous reader poll. Unscientific, not investment advice.
About Savara
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
- Founded
- 1995
- CEO
- Mr. Matthew Pauls, J.D.,M.B.A.
- Employees
- 70
- Headquarters
- Langhorne, Pennsylvania, United States of America
- Fiscal year end
- 12-31
- Website
- savarapharma.com
Company profile
- Exchange
- US
- Symbol
- SVRA
- Market-cap rank
- #3247
- Market cap
- 961.55M
- Float cap
- 379.39M
- Shares out
- 205.46M
- Float shares
- 81.07M
Sectors & themes
Quote time 2026-10-08 10:11:05 · For reference only, not investment advice and not tailored to your situation.